Drug Trial Radar · NCT05408546
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
May 24, 2023
Primary completion
Aug 31, 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Translational Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II trial of TS23
Conditions
- Pulmonary Embolism
Interventions
TS23Drug
Monoclonal antibody to a2-antiplasmin
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- RV/LVTime frame: 48 hours after treatment
- Safety- BleedingTime frame: within 7 days of treatment
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center
Phoenix, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
Cedars Sinai Medical Center
Los Angeles, California
Cottage Hospital
Santa Barbara, California
Wellstar MCG Health Medical Center
Augusta, Georgia
Lifebridge Health
Baltimore, Maryland
Tuft University Hospital
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Wake Forest University/Atrium Health's Carolinas Medical Center
Winston-Salem, North Carolina
Fairview Hospital
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Temple University Hospital
Philadelphia, Pennsylvania
Texas Tech University Health Sciences Center at El Paso
El Paso, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.